Merck & Co., Inc. (MRK)
NYSE · Price as of · Nasdaq Real Time Price
- Analysts25
- Implied upside+8.1%
- Target range$105.00 to $186.00
- EPS expected$2.13 -18%
- A year ago$2.58
- Revenue expected$17.33B +0.3%
- Estimate range$1.80 to $2.29
- Priced move±7.7%
How Congress has done in MRK
Every purchase of MRK disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.
| Measure | MRK | SPY |
|---|---|---|
| Median 12-month return after purchase | +22.5% | +23.4% |
| Median difference vs SPY | +5.9% | — |
| Purchases that beat SPY | 14 of 25 (56%) | — |
| Members who bought | 14 | — |
Most frequent buyers: Jared Moskowitz (5), Gil Cisneros (3), Marjorie Taylor Greene (3), Daniel Goldman (2), Julie Johnson (2).
These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 6 of the 25 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.
Congress trades in MRK
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar FL | Sale | $1,001 - $15,000 | |
| 2026-08-19 | Maria Elvira Salazar FL | Purchase | $15,001 - $50,000 | |
| 2025-01-10 | Keith Self TX | Sale | $1,001 - $15,000 |
SEC filings
Merck & news
Articles that mention Merck & without it being the main subject.
Four Korean stocks hit their 30% daily limit on Moderna's cancer-vaccine trial win. Three actually work in mRNA, and the fourth makes semiconductor equipment.
Somagen, Naibec, Genexine and Samyang Biopharm all hit Korea's 30% daily limit on Moderna's cancer-vaccine trial win, and each has a disclosed mRNA business behind it, except one. Entutech hit the same limit riding a five-year-old rumor. It makes semiconductor equipment.
Moderna (MRNA) options bought for a penny Tuesday were worth $96 by Wednesday. That's a one-day gain of 965,200%.
MRNA call options bought for a penny on Tuesday were worth $96 a share by Wednesday, a 965,200% gain in one day, after Moderna's Merck-partnered melanoma vaccine trial succeeded. A $100 bet on them would have been worth $965,300 if sold at the high.
Frequently asked questions
When does MRK report earnings?
Merck & Co., Inc. (MRK) is scheduled to report quarterly results on October 29, 2026, before the open. The 18-analyst consensus is $2.13 per share on revenue of $17.33B for the quarter ended September 30, 2026, against $2.58 and $17.28B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters. The options market is pricing a move of about 7.7% in either direction on the report, based on the cost of the at-the-money straddle expiring October 30, 2026.
What do analysts expect for MRK?
25 analysts cover Merck & Co., Inc. (MRK). The consensus rating is Buy. The average price target is $158.28, in a range of $105.00 to $186.00.
Are insiders buying or selling MRK?
We have no qualifying Form 4 insider purchases or sales on record for Merck & Co., Inc. (MRK). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Has Congress made money trading MRK?
14 members of Congress have disclosed buying MRK in the last 5 years, 25 purchases in total. Measured over the 12 months after each trade date, the median purchase returned +22.5% against +23.4% for SPY over the same windows, and 14 of the 25 (56%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.
Where can I see MRK SEC filings?
We could not resolve current EDGAR filings for MRK. This usually means the ticker is a foreign or over-the-counter listing that does not file with the SEC.